Cancer Management and Research (Feb 2020)
Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML
Abstract
Guangfu Mu, Fangping Chen Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, People’s Republic of ChinaCorrespondence: Fangping ChenDepartment of Hematology, The Third Xiangya Hospital, Central South University, Tongzipo Road No. 138, Changsha, Hunan 410013, People’s Republic of ChinaTel/Fax +86 073 1861 8841Email [email protected]: AML1-ETO produced by t(8;21) abnomality has multiple effects on the leukemogenesis of acute myeloid leukemia (AML). SET domain, bifurcated 2 (SETDB2) can mediate gene silencing by trimethylation of the ninth lysine residue of histone H3 protein (H3K9) of the promoter and has been confirmed as an oncogene in many cancers. The role of SETDB2 in AML1-ETO positive AML is not clear.Methods: Quantitative reverse transcription PCR was performed to measure SETDB2 expression in bone marrow from AML patients and healthy people. Kaplan-Meier analysis was performed to investigate the effect of SETDB2 on prognosis of AML patients. Dual luciferase reporter gene assay, chromatin immunoprecipitation were performed to investigate the regulatory mechanism of AML1-ETO on SETDB2. CCK-8 and colony formation assay were performed to measure the effect of SETDB2 on leukemic cells.Results: SETDB2 is highly expressed in AML1-ETO positive AML. The overall survival, event-free and relapse-free survival rate of patients with high SETDB2 expression was lower than those of patients with low SETDB2 expression. SETDB2 is epigenetically upregulated by AML1-ETO fusion protein. Downregulation of SETDB2 expression significantly inhibits the proliferation and clonality of leukemic cells and promotes the sensitivity of leukemic cells to an epigenetic inhibitor JQ1.Conclusion: AML1-ETO/SETDB2 is a novel epigenetic pathway of leukemogenesis and SETDB2 is a potential therapeutic target of t(8;21) AML.Keywords: acute myeloid leukemia, AML1-ETO, SETDB2, epigenetic, clinical biomarker
